Restenosis after percutaneous angioplasty: the role of vascular inflammation

Martin Schillinger, Erich Minar, Martin Schillinger, Erich Minar

Abstract

Restenosis after endovascular treatment of atherosclerotic lesions in the peripheral, cerebrovascular, and coronary circulation is the major drawback of this minimally invasive technique. Although certain advances have been made during recent years to improve patency rates after percutaneous angioplasty, restenosis remains a challenging clinical problem. Understanding factors that contribute to the pathophysiology of late lumen loss is an effective strategy to improving patients' postangioplasty outcome. Vascular inflammation after balloon angioplasty or stent implantation has been identified as a cornerstone of the restenotic process, and several markers of inflammation have been referred to as potential predictors of outcome. This article reviews recent findings on the issue of inflammation and restenosis after percutaneous angioplasty with special attention given to the role of inflammatory parameters as markers for the restenosis risk in the peripheral vessel area.

References

    1. Adar R, Critchfield GC, Eddy DM. A confidence profile analysis of the results of femoropopliteal percutaneous transluminal angioplasty in the treatment of lower-extremity ischemia. J Vasc Surg. 1989;10:57–67.
    1. Ahmadi R, Willfort A, Lang W, et al. Carotid artery stenting: effect of learning and intermediate-term morphological outcome. J Endovasc Ther. 2001;8:539–46.
    1. Bauters C, Lamblin N, Amouyel P. Gene polymorphisms and outcome after coronary angioplasty. Curr Interv Cardiol Rep. 2001;3:281–6.
    1. Belch JJ, Shaw JW, Kirk G, et al. The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing percutaneous transluminal angioplasty. Circulation. 1997;95:2027–31.
    1. Berk BC, Weintraub WS, Alexander RW. Elevation of c-reactive protein in “active” coronary artery disease. Am J Cardiol. 1990;65:168–72.
    1. Blum A, Kaplan G, Vardinon N, et al. Serum amyloid type A may be a predictor or restenosis. Clin Cardiol. 1998;21:655–8.
    1. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortailiac occlusive disease. Radiology. 1997;204:87–96.
    1. Breuss JM, Cejna M, Bergmeister H, et al. Activation of nuclear factor-kappa B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation. 2002;105:633–8.
    1. Brull DJ, Montgomery HE, Sanders J, et al. Interleukin-6 gene −174G>C and −572G>C promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol. 2001;21:1457–63.
    1. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 1999;34:1512–21.
    1. Cejna M, Breuss JM, Bergmeister H, et al. Inhibition of neointimal formation after stent placement with adenovirus-mediated gene transfer of I kappa B alpha in the hypercholesterolemic rabbit model: initial results. Radiology. 2002;223:702–8.
    1. Cejna M, Thurnher SA, Illiasch H, et al. PTA vs Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomised study. J Vasc Interven Radiol. 2001;12:23–31.
    1. Cipollone F, Marini M, Fazia M, et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol. 2001;21:327–34.
    1. Diegeler A, Thiele H, Falk V, et al. Comparison of stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery. N Engl J Med. 2002;347:561–6.
    1. Dormandy JA, Rutherford B. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC) J Vasc Surg. 2000;31(1 Pt 2):S1–296.
    1. Duckers HJ, Boehm M, True AL, et al. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med. 2001;7:693–8.
    1. Ernst E. Fibrinogen as a cardiovascular risk factor: interrelationship with infections and inflammation. Eur Heart J. 1993;14:82–7.
    1. Exner M, Schillinger M, Minar E, et al. Heme oxygenase-1 microsatellite gene promoter polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther. 2001;8:433–40.
    1. Exner M, Schillinger M, Minar E, et al. Interleukin 6 genotype and restenosis after balloon angioplasty: initial observation. Radiology. 2004;231:839–44.
    1. Forrester JS, Fishbein M, Helfant R, et al. A paradigm for restenosis based on cell biological clues for the development of new preventive therapies. J Am Coll Cardiol. 1991;17:758–69.
    1. Gallino A, Mahler F, Probst P, et al. Percutaneous transluminal angioplasty of the arteries of the lower limbs: a 5 year follow-up. Circulation. 1984;70:619–23.
    1. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503–16.
    1. Haverkate F, Thompson SG, Pyke SDM, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462–6.
    1. Heinrich J, Schulte H, Schönfeld R, et al. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost. 1995;73:374–9.
    1. Ishikawa K, Sugawara D, Wang Xp, et al. Heme oxygenase-1 inhibits atherosclerotic lesion formation in LDL-receptor knockout mice. Circ Res. 2001;88:506–12.
    1. Jeans WD, Armstrong S, Cole SE, et al. Fate of patients undergoing transluminal angioplasty for lower-limb ischemia. Radiology. 1990;177:559–64.
    1. Jukema JW, Kastelein JJ. Tailored therapy to fit individual profiles Genetics and coronary artery disease. Ann N Y Acad Sci. 2000;902:17–24.
    1. Kamijikkoku S, Murohara T, Tayama S, et al. Acute myocardial infarction and increased soluble intercellular adhesion molecule-1: a marker of vascular inflammation and risk of early restenosis? Am Heart J. 1998;136:231–6.
    1. Kastrati A, Dirschinger J, Schomig A. Genetic risk factors and restenosis after percutaneous coronary interventions. Herz. 2000;25:34–46.
    1. Kimpara T, Takeda A, Watanabe K, et al. Microsatellite polymorphism in the human heme oxygenase-1 gene promoter and its application in association studies with Alzheimer and Parkinson disease. Hum Genet. 1997;100:145–7.
    1. Kornowski R, Hong MK, Tio FO, et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31:224–30.
    1. Krepel VM, van Andel GJ, van Erp WF, et al. Percutaneous transluminal angioplasty of femoropopliteal artery: initial and long term results. Radiology. 1985;156:325–8.
    1. Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 1996;144:537–47.
    1. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–43.
    1. Liuzzo G, Biasucci L, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417–24.
    1. Lusis AJ. Atherosclerosis. Nature. 2000;407:233–41.
    1. Maca T, Ahmadi R, Derfler K, et al. Elevated lipoprotein(a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females? Atherosclerosis. 1996;127:27–34.
    1. Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms and clinical application. FASEB J. 1988;2:2557–68.
    1. Matsi PJ, Manninen HI, Vanninen RL, et al. Femoropopliteal angioplasty in patients with claudication: primary and secondary patency in 140 limbs with 1–3-year follow-up. Radiology. 1994;191:727–33.
    1. Mendall MA, Patel P, Ballam L, et al. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996;312:1061–5.
    1. Mickelson JK, Lakkis NM, Villarreal-Levy G, et al. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? J Am Coll Cardiol. 1996;28:345–53.
    1. Minar E, Pokrajac B, Ahmadi R, et al. Brachytherapy for prophylaxis of restenosis after long-segment femoropopliteal angioplasty: pilot study. Radiology. 1998;208:173–9.
    1. Minar E, Pokrajac B, Maca T, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomised study. Circulation. 2000;102:2694–9.
    1. Morice MC, Serruys PW, Sousa JE, et al. A randomised comparison of a sirolymus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–80.
    1. O'Brian ER, Schwartz SM. Update of the biology and clinical study of restenosis. Trends Cardiovasc Med. 1994;4:169–78.
    1. Ohtani K, Egashira K, Usui M, et al. Inhibition of neointimal hyperplasia after balloon injury by cis-element “decoy” of early growth response gene-1 in hypercholesterolemic rabbits. Gene Ther. 2004;11:126–32.
    1. Orford JL, Selwyn AP, Ganz P, et al. The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol. 2000;86(Suppl):6H–11H.
    1. Pepys MB. The acute phase response and C-reactive protein. In: Weatherall DJ, Ledingham JGG, Warrell DA, editors. Oxford textbook of medicine, third edition. Oxford: Oxford Univ Pr.; 1995. pp. 1527–33.
    1. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein (Review) Adv Immunol. 1983;34:141–212.
    1. Pietersma A, Kofflard M, de Wit LE, et al. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation. 1995;91:1320–5.
    1. Roguin A, Hochberg I, Nikolsky E, et al. Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 2001;87:330–2.
    1. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999;340:115–26.
    1. Schillinger M, Exner M, Mlekusch W, et al. Vascular inflammation and percutaneous transluminal of the femoropopliteal artery: association with restenosis. Radiology. 2002a;225:21–6.
    1. Schillinger M, Exner M, Mlekusch W, et al. Fibrinogen and restenosis after endovascular treatment of the iliac arteries: a marker of inflammation or coagulation? Thromb Haemost. 2002b;87:959–65.
    1. Schillinger M, Exner M, Mlekusch W, et al. Balloon angioplasty and stent implantation induce a vascular inflammatory reaction. J Endovasc Ther. 2002c;9:59–66.
    1. Schillinger M, Exner M, Mlekusch W, et al. Inflammatory response to stent implantation: differences in femoropopliteal, iliac, and carotid arteries. Radiology. 2002d;224:529–35.
    1. Schillinger M, Exner M, Mlekusch W, et al. Heme oxygenase-1 genotype is a vascular anti-inflammatory factor following balloon angioplasty. J Endovasc Ther. 2002e;9:385–94.
    1. Schillinger M, Exner M, Mlekusch W, et al. Endovascular revascularisation below the knee: 6 months results and predictive value of C-reactive protein level. Radiology. 2003a;227:419–25.
    1. Schillinger M, Exner M, Mlekusch W, et al. Acute phase response after stent implantation in the carotid artery: association with 6 months instent restenosis. Radiology. 2003b;227:516–21.
    1. Schillinger M, Exner M, Minar E, et al. Heme oxygenase-1 genotype and restenosis after balloon angioplasty: a novel vascular protective factor. J Am Coll Cardiol. 2004;43:950–7.
    1. Schillinger M, Haumer M, Schlerka G, et al. Restenosis after percutaneous transluminal angioplasty in patients with peripheral artery disease: the role of inflammation. J Endovasc Ther. 2001;8:477–83.
    1. Serrano CV, Ramires JA, Venturinelli M, et al. Coronary angioplasty results in leucocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol. 1997;29:1276–83.
    1. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007–11.
    1. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a procine coronary model. Circulation. 2001;104:1188–93.
    1. Tanguay JF, Geoffroy P, Sirois MG, et al. Prevention of in-stent restenosis via reduction of thrombo-inflammatory reactions with recombinant P-selectin glycoprotein ligand-1. Thromb Haemost. 2004;91:1186–93.
    1. Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem. 1969;244:6388–94.
    1. Tetteroo E, van der Graaf Y, Bosch JL, et al. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study group. Lancet. 1998;351:1153–9.
    1. Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386–92.
    1. Tsakiris DA, Tschopl M, Jager K, et al. Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis. 1999;142:193–200.
    1. Tschöpl M, Tsakiris DA, Marbet GA, et al. Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. Arterioscler Thromb Vasc Biol. 1997;17:3208–14.
    1. Tulis DA, Durante W, Peyton KJ, et al. Heme oxygenase-1 attenuates vascular remodeling following balloon injury in rat carotid arteries. Atherosclerosis. 2001;155:113–22.
    1. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913–19.
    1. Versaci F, Gaspardone A, Tomai F, et al. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study) J Am Coll Cardiol. 2002;40:1935–42.
    1. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol. 1999;10:499–506.
    1. Wilcox JN, Okamoto EI, Nakahara KI, et al. Perivascular responses after angioplasty which may contribute to postangioplasty restenosis: a role for circulating myofibroblasts precursors? Ann N Y Acad Sci. 2001;947:68–90.
    1. Yamada N, Yamaya M, Okinaga S, et al. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet. 2000;66:187–95.
    1. Yokoyama T, Miyauchi K, Kurata T. Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stenting. Atherosclerosis. 2004;174:253–9.
    1. Young B, Gleeson M, Cripps AW. C-reactive protein: a critical review. Pathology. 1991;23:118–24.
    1. Yutani C, Ishibashi-Ueda H, Suzuki T, et al. Histologic evidence of foreign body granulation tissue and de novo lesions in patients with coronary stent stenosis. Cardiology. 1999;92:171–7.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner